Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Liang Wei, … , Lin Zhang, Jian Yu
Liang Wei, … , Lin Zhang, Jian Yu
Published October 4, 2016
Citation Information: J Clin Invest. 2016;126(11):4076-4087. https://doi.org/10.1172/JCI88410.
View: Text | PDF
Research Article Gastroenterology Stem cells

Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice

  • Text
  • PDF
Abstract

Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is no FDA-approved agent for the prevention or treatment of radiation-induced intestinal injury. In this study, we have shown that PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration. PD treatment also enhanced LGR5+ stem cell survival and regeneration after radiation. PD was an on-target inhibitor of RB phosphorylation and blocked G1/S transition in the intestinal crypts. PD treatment strongly but reversibly inhibited radiation-induced p53 activation, which blocked p53-upregulated modulator of apoptosis–dependent (PUMA-dependent) apoptosis without affecting p21-dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining. Further, deletion of PUMA synergized with PD treatment for even greater intestinal radioprotection. Our results demonstrate that the cell cycle critically regulates the DNA damage response and survival of intestinal stem cells and support the concept that pharmacological quiescence is a potentially highly effective and selective strategy for intestinal radioprotection.

Authors

Liang Wei, Brian J. Leibowitz, Xinwei Wang, Michael Epperly, Joel Greenberger, Lin Zhang, Jian Yu

×

Figure 3

PD blocks IR-induced crypt apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
PD blocks IR-induced crypt apoptosis.
Mice were pretreated with vehicle,...
Mice were pretreated with vehicle, PD, or LEE and subjected to 15 Gy TBI. The small intestine was analyzed at the indicated time points. (A) Representative images of TUNEL and cleaved caspase-3 (CASP-3) staining of intestinal sections at 4 hours. Scale bars: 20 μm. (B) Quantitation of TUNEL+ and cleaved caspase-3+ crypt cells at 4 and 24 hours. (C) Fractions of cleaved caspase-3+ crypt cells at 4 hours based on cell positions. (D) Quantification of TUNEL and BrdU index at 4 hours and regenerated crypts at 96 hours in LEE-treated and control (Ctrl) mice. (E) Intestinal expression of the indicated proteins analyzed by Western blotting. β-Actin was used as the loading control. Lysates were pooled from 3 mice per group. Replicate samples run on separate gels are presented. (F) Intestinal relative expression of the indicated mRNAs versus the nontreated mice. cDNA was synthesized from RNA pooled from 3 mice per group. Similar results were obtained in at least 3 independent experiments for Western blotting and RT-PCR. (B–D and F) Values represent the mean ± SEM; N = 3 mice in each group. *P < 0.05, **P < 0.01, and ***P < 0.001, vehicle versus PD or LEE treatment, by unpaired, 2-tailed Student’s t test.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts